|
1
|
Mazzone T, Chait A and Plutzky J:
Cardiovascular disease risk in type 2 diabetes mellitus: Insights
from mechanistic studies. Lancet. 371:1800–1809. 2008. View Article : Google Scholar :
|
|
2
|
Zhong J, Maiseyeu A, Davis SN and
Rajagopalan S: DPP4 in cardiometabolic disease: Recent insights
from the laboratory and clinical trials of DPP4 inhibition. Circ
Res. 116:1491–1504. 2015. View Article : Google Scholar :
|
|
3
|
Libby P: Inflammation in atherosclerosis.
Nature. 420:868–874. 2002. View Article : Google Scholar
|
|
4
|
Drucker DJ and Nauck MA: The incretin
system: Glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705.
2006. View Article : Google Scholar
|
|
5
|
Ussher JR and Drucker DJ: Cardiovascular
biology of the incretin system. Endocr Rev. 33:187–215. 2012.
View Article : Google Scholar :
|
|
6
|
Drucker D, Easley C and Kirkpatrick P:
Sitagliptin. Nat Rev Drug Discov. 6:109–110. 2007. View Article : Google Scholar
|
|
7
|
Matsubara J, Sugiyama S, Sugamura K,
Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K,
Konishi M, et al: A dipeptidyl peptidase-4 inhibitor,
des-fluoro-sitagliptin, improves endothelial function and reduces
atherosclerotic lesion formation in apolipoprotein E-deficient
mice. J Am Coll Cardiol. 59:265–276. 2012. View Article : Google Scholar
|
|
8
|
Zeng Y, Li C, Guan M, Zheng Z, Li J, Xu W,
Wang L, He F and Xue Y: The DPP-4 inhibitor sitagliptin attenuates
the progress of atherosclerosis in apolipoprotein-E-knockout mice
via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol.
13:322014. View Article : Google Scholar :
|
|
9
|
Hardie DG, Ross FA and Hawley SA: AMPK: A
nutrient and energy sensor that maintains energy homeostasis. Nat
Rev Mol Cell Biol. 13:251–262. 2012. View
Article : Google Scholar
|
|
10
|
Eid AA, Ford BM, Block K, Kasinath BS,
Gorin Y, Ghosh-Choudhury G, Barnes JL and Abboud HE: AMP-activated
protein kinase (AMPK) negatively regulates Nox4-dependent
activation of p53 and epithelial cell apoptosis in diabetes. J Biol
Chem. 285:37503–37512. 2010. View Article : Google Scholar :
|
|
11
|
Ido Y, Carling D and Ruderman N:
Hyperglycemia-induced apoptosis in human umbilical vein endothelial
cells: Inhibition by the AMP-activated protein kinase activation.
Diabetes. 51:159–167. 2002. View Article : Google Scholar
|
|
12
|
Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu
C, Viollet B, Yan D and Zou MH: AMPKalpha2 deletion causes aberrant
expression and activation of NAD(P)H oxidase and consequent
endothelial dysfunction in vivo: Role of 26S proteasomes. Circ Res.
106:1117–1128. 2010. View Article : Google Scholar :
|
|
13
|
Colombo SL and Moncada S: AMPKalpha1
regulates the antioxidant status of vascular endothelial cells.
Biochem J. 421:163–169. 2009. View Article : Google Scholar
|
|
14
|
Pan B, Yu B, Ren H, Willard B, Pan L, Zu
L, Shen X, Ma Y, Li X, Niu C, et al: High-density lipoprotein
nitration and chlorination catalyzed by myeloperoxidase impair its
effect of promoting endothelial repair. Free Radic Biol Med.
60:272–281. 2013. View Article : Google Scholar
|
|
15
|
Mao G, Liu Y, Fang X, Liu Y, Fang L, Lin
L, Liu X and Wang N: Tumor-derived microRNA-494 promotes
angiogenesis in non-small cell lung cancer. Angiogenesis.
18:373–382. 2015. View Article : Google Scholar
|
|
16
|
Yin R, Fang L, Li Y, Xue P, Li Y, Guan Y,
Chang Y, Chen C and Wang N: Pro-inflammatory Macrophages suppress
PPARγ activity in Adipocytes via S-nitrosylation. Free Radic Biol
Med. 89:895–905. 2015. View Article : Google Scholar
|
|
17
|
Paneni F, Mocharla P, Akhmedov A,
Costantino S, Osto E, Volpe M, Lüscher TF and Cosentino F: Gene
silencing of the mitochondrial adaptor p66(Shc) suppresses vascular
hyperglycemic memory in diabetes. Circ Res. 111:278–289. 2012.
View Article : Google Scholar
|
|
18
|
Yee C, Yang W and Hekimi S: The intrinsic
apoptosis pathway mediates the pro-longevity response to
mitochondrial ROS in C. Elegans. Cell. 157:897–909. 2014.
View Article : Google Scholar :
|
|
19
|
Shah Z, Pineda C, Kampfrath T, Maiseyeu A,
Ying Z, Racoma I, Deiuliis J, Xu X, Sun Q, Moffatt-Bruce S, et al:
Acute DPP-4 inhibition modulates vascular tone through GLP-1
independent pathways. Vascul Pharmacol. 55:2–9. 2011. View Article : Google Scholar :
|
|
20
|
Ishii M, Shibata R, Kondo K, Kambara T,
Shimizu Y, Tanigawa T, Bando YK, Nishimura M, Ouchi N and Murohara
T: Vildagliptin stimulates endothelial cell network formation and
ischemia-induced revascularization via an endothelial nitric-oxide
synthase-dependent mechanism. J Biol Chem. 289:27235–27245. 2014.
View Article : Google Scholar :
|
|
21
|
Aroor AR, Sowers JR, Bender SB, Nistala R,
Garro M, Mugerfeld I, Hayden MR, Johnson MS, Salam M,
Whaley-Connell A and Demarco VG: Dipeptidylpeptidase inhibition is
associated with improvement in blood pressure and diastolic
function in insulin-resistant male Zucker obese rats.
Endocrinology. 154:2501–2513. 2013. View Article : Google Scholar :
|
|
22
|
Oakhill JS, Steel R, Chen ZP, Scott JW,
Ling N, Tam S and Kemp BE: AMPK is a direct adenylate
charge-regulated protein kinase. Science. 332:1433–1435. 2011.
View Article : Google Scholar
|
|
23
|
Viollet B, Lantier L, Devin-Leclerc J,
Hebrard S, Amouyal C, Mounier R, Foretz M and Andreelli F:
Targeting the AMPK pathway for the treatment of Type 2 diabetes.
Front Biosci (Landmark Ed). 14:3380–3400. 2009. View Article : Google Scholar :
|
|
24
|
Xu Q and Si LY: Protective effects of
AMP-activated protein kinase in the cardiovascular system. J Cell
Mol Med. 14:2604–2613. 2010. View Article : Google Scholar :
|
|
25
|
Hawley SA, Ross FA, Chevtzoff C, Green KA,
Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM and
Hardie DG: Use of cells expressing gamma subunit variants to
identify diverse mechanisms of AMPK activation. Cell Metab.
11:554–565. 2010. View Article : Google Scholar :
|
|
26
|
Bhatt MP, Lim YC, Kim YM and Ha KS:
C-peptide activates AMPKα and prevents ROS-mediated mitochondrial
fission and endothelial apoptosis in diabetes. Diabetes.
62:3851–3862. 2013. View Article : Google Scholar :
|
|
27
|
Hawley SA, Pan DA, Mustard KJ, Ross L,
Bain J, Edelman AM, Frenguelli BG and Hardie DG:
Calmodulin-dependent protein kinase kinase-beta is an alternative
upstream kinase for AMP-activated protein kinase. Cell Metab.
2:9–19. 2005. View Article : Google Scholar
|
|
28
|
Shaw RJ, Kosmatka M, Bardeesy N, Hurley
RL, Witters LA, DePinho RA and Cantley LC: The tumor suppressor
LKB1 kinase directly activates AMP-activated kinase and regulates
apoptosis in response to energy stress. In: Proc Natl Acad Sci USA.
101. pp. 3329–3335. 2004; View Article : Google Scholar :
|
|
29
|
Fisslthaler B and Fleming I: Activation
and signaling by the AMP-activated protein kinase in endothelial
cells. Circ Res. 105:114–127. 2009. View Article : Google Scholar
|
|
30
|
Liu L, Liu J, Wong WT, Tian XY, Lau CW,
Wang YX, Xu G, Pu Y, Zhu Z, Xu A, et al: Dipeptidyl peptidase 4
inhibitor sitagliptin protects endothelial function in hypertension
through a glucagon-like peptide 1-dependent mechanism.
Hypertension. 60:833–841. 2012. View Article : Google Scholar
|
